MGI Announces Commercial Launch of HotMPS High-Throughput Sequencing Kit* and Instrument** in Germany

MGI Tech Co. Ltd. (MGI), a global leader and innovator in the field of life sciences, is thrilled to announce the commercial availability of its cutting-edge HotMPS reagents and sequencing instrument in Germany, effective from 9th August 2022. This launch signifies another significant milestone for MGI in expanding its presence and supporting the thriving German market, which has been at the forefront of promoting and implementing genomic medicine.

MGI's Commitment to the German Market

"We are delighted to bring our proven DNBSEQ™ technology to customers and partners in Germany once again," expressed Dr. Yong Hou, General Manager of MGI Europe and Africa. He further emphasized the importance of the German market, referring to it as MGI's most crucial European market. The introduction of the HotMPS chemistry in Germany not only solidifies MGI's dedication to this high-potential market but also demonstrates their commitment to advancing genomic medicine.

Unveiling Details at ICG-17 and MEDICA 2022

Further information regarding the German launch will be disclosed during the 17th Annual Meeting of the International Conference of Genomics (ICG-17) in Riga, with registration for the livestream available here. In addition, MGI plans to showcase the DNBSEQ-G400 sequencing platform, exclusively designed for HotMPS chemistry, at MEDICA 2022, scheduled to take place from 14th to 17th November in Düsseldorf. Furthermore, MGI will actively participate as a sponsor in the 32nd GfH Annual Meeting in Kassel, from 15th to 17th March 2023.

The Revolutionary HotMPS Sequencing Chemistry

MGI's HotMPS sequencing chemistry, developed for use on the DNBSEQ-G400 sequencer, has already been successfully rolled out in selected countries. During the 55th European Human Genetics (ESHG) Conference held in Vienna on 11th June, end users presented data generated using this chemistry, which was met with great enthusiasm. The innovative HotMPS chemistry, built upon MGI's proprietary DNBSEQ™ technology and its combinatorial Probe Anchor Synthesis (cPAS) technology, offers remarkable advantages such as low error rate, low duplication rate, and low index hopping. It also demonstrates breakthroughs in nucleotides and enzymes used in the sequencing process. Moreover, this chemistry provides stronger signals, reduces systematic sequence-based errors, and is compatible with commonly used library preparation methods.

Endorsement from Prof. Olaf Rieß

Prof. Olaf Rieß, Head of the Institute of Medical Genetics and Applied Genomics at The University of Tübingen, praised MGI's DNBSEQ™ technology for enabling ambitious research projects in their laboratories. Prof. Rieß expressed excitement about the arrival of MGI's HotMPS chemistry in Germany, anticipating that it would contribute to significant research advancements in the field.

MGI's Commitment to Innovation

MGI remains steadfast in its commitment to lead life science through intelligent innovation. With a dedicated team of salespeople, Field Application Specialists, and Field Service Engineers based in their recently opened Wehrheim office, MGI is fully prepared to support the installation of the new sequencers. Their primary goal is to empower customers and fulfill their sequencing needs by delivering performance, quality, availability, and affordability.

Conclusion

The commercial launch of MGI's HotMPS High-Throughput Sequencing Kit and Instrument in Germany signifies a major advancement in the field of life sciences. MGI's proven DNBSEQ™ technology, coupled with the revolutionary HotMPS chemistry, promises to revolutionize genomic medicine and empower researchers across Germany. With their unwavering commitment to innovation and customer support, MGI is poised to shape the future of healthcare and contribute to groundbreaking discoveries in life science research.

About MGI

MGI Tech Co., Ltd. (MGI) is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI focuses on research & development, production, and sales of sequencing instruments***, reagents***, and related products to support life science research, agriculture, precision medicine, and healthcare. MGI's mission is to develop and promote advanced life science tools for future healthcare. As of December 2021, MGI has a footprint that spans across more than 80 countries and regions, serves over 1,300 international users, and employs more than 2,050 professionals globally, around 35% of which are R&D personnel. For more information, please visit the MGI website or connect on Twitter, LinkedIn, or YouTube.